Monday, July 16, 2018

Human Longevity Names Interim CEO and COO

San Diego-based Human Longevity, which is developing genomics-powered, health intelligence software, said on Friday that it has named David Karow, M.D., Ph.D., as its Interim CEO. Karow was previously Human Longevity's Chief of Radiogenomics. Karow has previously been a researcher at UC San Diego, UCLA, and the University of Michigan, Ann Arbor. The company also said Scott Sorenson will serve as Interim Chief Operations Officer; Sorenson was most recently Chief Technology Officer at the company, having previously been at Ancestry. Human Longevity is venture backed by Illumina, Celgene, GE Ventures, and others, and raised a big round of funding in 2016 worth $220M. Human Longevity--which had been headed by genomics pioneer J. Craig Venter--has seen a huge amount of executive turnover in the last year or so.